Search research articles
Contact Us
Filters
Showing results (41-50 of 74) with videos related to
Page
of 8
Sort By:
Plos One
|
March 4, 2014
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells
Maria Teresa Di Martino, Annamaria Gullà, Maria Eugenia Gallo Cantafio, et al.
Clinical Pharmacology and Therapeutics
|
February 11, 2019
Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study
Mariamena Arbitrio, Francesca Scionti, Emanuela Altomare, et al.
American Journal of Hematology
|
August 14, 2013
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy
Alessandro Rambaldi, Cristina Boschini, Giuseppe Gritti, et al.
Cancers
|
September 13, 2025
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy
Daniele Caracciolo, Filippo Antonio Canale, Virginia Naso, et al.
Blood
|
August 19, 2024
An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma
Katia Grillone, Serena Ascrizzi, Paolo Cremaschi, et al.
Haematologica
|
February 22, 2020
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma
Daniele Caracciolo, Francesca Scionti, Giada Juli, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 15, 2016
Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study
Marco Ruella, Andrea Riccardo Filippi, Riccardo Bruna, et al.
International Journal of Molecular Sciences
|
September 23, 2022
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma
Katia Grillone, Caterina Riillo, Roberta Rocca, et al.
Journal of Translational Medicine
|
May 4, 2023
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer
Caterina Riillo, Nicoletta Polerà, Maria Teresa Di Martino, et al.
Annals of Hematology
|
June 6, 2013
Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma
Simone Ferrero, Luigia Monitillo, Barbara Mantoan, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 74) with videos related to
Sort By:
Page
of 8
Plos One
|
March 4, 2014
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells
Maria Teresa Di Martino, Annamaria Gullà, Maria Eugenia Gallo Cantafio, et al.
Clinical Pharmacology and Therapeutics
|
February 11, 2019
Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study
Mariamena Arbitrio, Francesca Scionti, Emanuela Altomare, et al.
American Journal of Hematology
|
August 14, 2013
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy
Alessandro Rambaldi, Cristina Boschini, Giuseppe Gritti, et al.
Cancers
|
September 13, 2025
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy
Daniele Caracciolo, Filippo Antonio Canale, Virginia Naso, et al.
Blood
|
August 19, 2024
An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma
Katia Grillone, Serena Ascrizzi, Paolo Cremaschi, et al.
Haematologica
|
February 22, 2020
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma
Daniele Caracciolo, Francesca Scionti, Giada Juli, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 15, 2016
Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study
Marco Ruella, Andrea Riccardo Filippi, Riccardo Bruna, et al.
International Journal of Molecular Sciences
|
September 23, 2022
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma
Katia Grillone, Caterina Riillo, Roberta Rocca, et al.
Journal of Translational Medicine
|
May 4, 2023
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer
Caterina Riillo, Nicoletta Polerà, Maria Teresa Di Martino, et al.
Annals of Hematology
|
June 6, 2013
Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma
Simone Ferrero, Luigia Monitillo, Barbara Mantoan, et al.
Page
of 8